A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

A Phase 2 study testing PM01183 in people with Breast Cancer, run by PharmaMar at 9 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the… Read more about this study

Who is it for?: Ages 18 to 75 years, women only
Conditions the study is for: Breast Cancer
What is being tested?: PM01183
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 111 participants
Where: 9 sitesin 2 countries
Study dates: 13 Jun 2012to Oct 2018
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
Women only
No healthy volunteers
Adult, Older adult

Who may be able to join

Women ≥ 18 and ≤ 75 years of age.
Voluntary signed informed consent form (ICF).
Proven diagnosis of metastatic breast cancer (MBC).
At least one, but no more than three, prior chemotherapy regimens for MBC.
Patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.
Disease evaluable for response by specific appropriate criteria.

Show all 14Show fewer

No or minimal disease-related symptoms not affecting patient daily activities.
Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)
Wash out periods prior to Day 1 of Cycle 1:
At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/investigational therapy
Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.
Patients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.
Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)
Prior treatment with PARP inhibitors (Patients in Cohort A1)

Who cannot join

Prior treatment with PM01183 or trabectedin.
Extensive prior RT.
Prior or concurrent malignant disease unless cured for more than five years.
Exceptions are breast cancer in the other breast.
Uncommon or rare subtypes of breast cancer.
Symptomatic or progressive brain metastases.

Show all 13Show fewer

Bone-limited and exclusively metastases.
Relevant diseases or clinical situations which may increase patient's risk:
History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV).
Known muscular disease or functional alteration
Pregnant or breastfeeding women.
Impending need for immediate RT for symptomatic relief.
Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.

Trial locations and contacts

9 sites in 2 countries.

Country

City, postcode or hospital

9 sites in 2 countries

United States5 sites

Massachusetts General Hospital
Boston, Massachusetts, 02114
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, 10065
Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104
Stanford Women's Cancer Center
Stanford, California, 94305

Other trials in United States

Spain4 sites

Complexo Hospitalario Universitario A Coruña
A Coruña, A Coruña, 15006
Hospital Universitari Vall d'Hebron
Barcelona, 08035
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, 15706
Hospital Clínico Universitario de Valencia
Valencia, 46010

Other trials in Spain

About this study

Official title: A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Read the detailed description

A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer to assess the antitumor activity of PM01183 in terms of overall response rate (ORR), duration of response (DR),clinical benefit [ORR or stable disease lasting over three months (SD > 3 months)], progression free survival (PFS), and one-year overall survival (1y-OS) and to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in MBC patients, to explore the activity of PM01183 in specific breast cancer subpopulations according to hormonal receptor status, HER-2 overexpression, number and/or type of prior therapies, or according to other available histological/molecular classifications, to evaluate the safety profile of this PM01183 administration schedule [Day 1 every three weeks (q3wk)] in this patient population, to analyze the pharmacokinetics (PK) of PM01183 in this patient population, to explore PK/PD (pharmacokinetic/ pharmacodynamic) correlations, if applicable and to evaluate the pharmacogenomic (PGx) expression profile of selected putative markers potentially predictive of response to PM01183, in tissues from tumor samples.

Conditions: Breast Cancer
Being tested: PM01183
Keywords: Breast cancer, PM01183, lurbinectedin, Pharma Mar
Medical subject headings: Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PM01183Drug
PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial

Study groups in NCT01525589
Study group	Role	What they receive
PM01183	Experimental	Not described Receives: Drug: PM01183

What is being measured

The primary outcome is the main question the study is designed to answer.

Overall Response Rate (ORR)
The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR >=30% decrease in the sum of the longest diameter of target lesions.
Measured: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Overall Response
Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: >=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.
Measured: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment

Secondary outcomes (11)

Duration of Response
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: >=30% decrease in the sum of the longest diameter of target lesions.
Measured: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Duration of Response Rate at 6 Months
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: >=30% decrease in the sum of the longest diameter of target lesions.
Measured: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 6 months
Duration of Response Rate at 12 Months
Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: >=30% decrease in the sum of the longest diameter of target lesions.
Measured: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 12 months
Clinical Benefit Rate
Clinical benefit, defined as the percentage of patients with ORR or SD lasting over three months (SD >3 months).
The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR >=30% decrease in the sum of the longest diameter of target lesions.
SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Measured: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Progression-free Survival (PFS)
Progression-free survival (PFS) is defined as the period of time from the date of first infusion to the date of progression disease, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: 36 months
Progression-free Survival at 3 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 3 months
Progression-free Survival at 6 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 6 months
Progression-free Survival at 12 Months
Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 12 months
Overall Survival (OS)
Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact
Measured: 36 months
Overall Survival Rate at 12 Months
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact
Measured: Time from the date of first infusion to the date of death or last contact, up to 12 months
Overall Survival Rate at 18 Months
Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact.
Measured: Time from the date of first infusion to the date of death or last contact, up to 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

13 Jun 2012Oct 2018

First posted3 Feb 2012 (estimated)
Study start13 Jun 2012
Primary completionOct 2018
Study completionOct 2018

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Breast CancerStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 111 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01525589
Sponsor's protocol ID: PM1183-B-003-11
Status last verified: Nov 2018
First submitted: 30 Jan 2012
Last updated: 25 Sep 2020
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Publications

Fernandez-Teruel C, Lubomirov R, Fudio S. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin. J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9.
PubMed 33914350
Cruz C, Llop-Guevara A, Garber JE, Arun BK, Perez Fidalgo JA, Lluch A, Telli ML, Fernandez C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Perez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmana J, Isakoff SJ. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.
PubMed 30240327

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

All Breast Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
ClinicalTrials.gov ID: NCT01525589
Acronym / sponsor ID: PM1183-B-003-11
Conditions: Breast Cancer
Keywords: Breast cancer, PM01183, lurbinectedin, Pharma Mar
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 111 participants (actual)
Lead sponsor: PharmaMarIndustry (pharma, biotech, devices)
Study start: 13 Jun 2012 (actual)
Primary completion: Oct 2018 (actual)
Study completion: Oct 2018 (actual)
First posted: 3 Feb 2012 (estimated)
Results: Posted 25 Sep 2020

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
PM01183	Experimental	Drug: PM01183

Who may qualify

Ages: 18 to 75 years
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (14 listed)

Women ≥ 18 and ≤ 75 years of age.
Voluntary signed informed consent form (ICF).
Proven diagnosis of metastatic breast cancer (MBC).
At least one, but no more than three, prior chemotherapy regimens for MBC.
Patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.

Key exclusion criteria (13 listed)

Prior treatment with PM01183 or trabectedin.
Extensive prior RT.
Prior or concurrent malignant disease unless cured for more than five years.
Exceptions are breast cancer in the other breast.
Uncommon or rare subtypes of breast cancer.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
PM01183PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial	Drug	PM01183

Primary outcome

Overall Response Rate (ORR)
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR >=30% decrease in the sum of the longest diameter of target lesions.
Overall Response
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: >=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.

11 secondary outcomes

Duration of Response
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Duration of Response Rate at 6 Months
Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 6 months
Duration of Response Rate at 12 Months
Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 12 months
Clinical Benefit Rate
Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Progression-free Survival (PFS)
Time frame: 36 months
Progression-free Survival at 3 Months
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 3 months
Progression-free Survival at 6 Months
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 6 months
Progression-free Survival at 12 Months
Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 12 months
Overall Survival (OS)
Time frame: 36 months
Overall Survival Rate at 12 Months
Time frame: Time from the date of first infusion to the date of death or last contact, up to 12 months
Overall Survival Rate at 18 Months
Time frame: Time from the date of first infusion to the date of death or last contact, up to 18 months

Results and safety

Results posted to the registry on 25 Sep 2020, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Cohort A (BRCA+)	56	0
Cohort A1 (BRCA+/PARPi)	20	0
Cohort B (Unselected)	35	0

Primary outcome: Overall Response Rate (ORR)

Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment. Number (95% Confidence Interval). Unit: percentage

Measure	Cohort A (BRCA+) n = 54	Cohort A1 (BRCA+/PARPi) n = 20	Cohort B (Unselected) n = 34
Value	40.7 (27.6 to 55.0)	5.0 (0.1 to 24.9)	8.8 (1.9 to 23.7)

Population analysed: Cohort A: Two patients never treated; Cohort B: 1 patient due to lack of post-baseline tumor assessments

Primary outcome: Overall Response

Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment. Count of participants. Unit: Participants

Measure	Cohort A (BRCA+) n = 54	Cohort A1 (BRCA+/PARPi) n = 20	Cohort B (Unselected) n = 34
CR	2	0	0
PR	20	1	3
SD	24	9	17
PD	8	10	13
TF	0	0	1

Population analysed: Cohort A: Two patients never treated; Cohort B: 1 patient due to lack of post-baseline tumor assessments

11 secondary outcomes are reported in the full results.

Adverse events

Time frame: Participants were assessed through study completion, aproximately 6 years. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Cohort A (BRCA+)	14 of 54 (25.9%)	54 of 54 (100%)	40 of 54
Cohort A1 (BRCA+/PARPi)	5 of 20 (25%)	20 of 20 (100%)	13 of 20
Cohort B (Unselected)	8 of 35 (22.9%)	34 of 35 (97.1%)	30 of 35

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2020.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 33914350Fernandez-Teruel C, Lubomirov R, Fudio S. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin. J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9.
Derived from this study: PubMed 30240327Cruz C, Llop-Guevara A, Garber JE, Arun BK, Perez Fidalgo JA, Lluch A, Telli ML, Fernandez C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Perez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmana J, Isakoff SJ. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.

Related trials for Breast Cancer

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

9 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing PM01183 in people with Breast Cancer, run by PharmaMar at 9 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in United States, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Response Rate (ORR) (time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01525589, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2020.